[
  {
    "clause_index": 4,
    "start_char": 1232,
    "end_char": 4348,
    "original": "5.2 Supply 5.3 Trademark Rights 5.4 Commercial Expenses Article 6. Payments 6.1 Upfront Payment 6.2 Funding to Support Development of The Product 6.3 Regulatory Milestones 6.4 Sales Milestones 6.5 Supply Payments Article 7. Payments, Books and Records 7.1 Payment Method US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 7.2 Currency Conversion 7.3 Taxes 7.4 Records 7.5 Audits 7.6 Late Payments Article 8. Confidentiality 8.1 Confidential Information 8.2 Exceptions 8.3 Permitted Disclosures 8.4 Confidentiality of this Agreement and its Terms 8.5 Public Announcements 8.6 Publication 8.7 Prior Non-Disclosure Agreements 8.8 Equitable Relief Article 9. Intellectual Property Ownership and Enforcement 9.1 Ownership of Intellectual Property 9.2 Zogenix Patent Prosecution and Maintenance 9.3 Infringement by Third Parties 9.4 Third Party Intellectual Property Rights 9.5 Patent Term Restoration 9.6 Patent Marking 9.7 Zogenix Trademarks 9.8 Product Trademarks Article 10. Representations, Warranties and Covenants\u037e Limitation of Liability 10.1 Mutual Representations, Warranties and Covenants 10.2 Representations, Warranties and Covenants of Distributor 10.3 Representations and Warranties of Zogenix 10.4 Disclaimer 10.5 Limitation of Liability Article 11. Indemnification 11.1 Indemnification of Zogenix 11.2 Indemnification of Distributor 11.3 Procedure 11.4 Insurance Article 12. Term and Termination 12.1 Term 12.2 Termination 12.3 Rights on Termination 12.4 Exercise of Right to Terminate 12.5 Damages\u037e Relief 12.6 Accrued Obligations\u037e Survival US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 Article 13. Dispute Resolution 13.1 Objective 13.2 Resolution by Executives 13.3 Arbitration Article 14. General Provisions 14.1 Governing Law 14.2 Force Majeure 14.3 Assignment 14.4 Severability 14.5 Notices 14.6 Entire Agreement\u037e Amendments 14.7 Headings 14.8 Independent Contractors 14.9 Waiver 14.1 Cumulative Remedies 14.11 Waiver of Rule of Construction 14.12 Interpretation 14.13 No Third Party Beneficiaries 14.14 English Language 14.15 Counterparts 14.16 Further Actions US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 List of Exhibits Exhibit 1.70  Unlabeled Drug Product Exhibit 1.74  Zogenix ZX008 Patents as of the Effective Date Exhibit 2.3  Material Terms of Supply Agreement Exhibit 4.2(a)  The initial version of the Regulatory Plan Exhibit 8.5(a)  Press Release Exhibit 9.7  Zogenix Trademarks Exhibit 9.8  Product Trademarks Exhibit 10.2(b)  Form of Compliance Certification US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 DISTRIBUTORSHIP AGREEMENT This DISTRIBUTORSHIP AGREEMENT (\u201cAgreement \u201d) is entered into as of March 18, 2019 (the \u201c Effective Date \u201d) by and between ZOGENIX, INC. , having a place of business at 5959 Horton Street, Suite 500, Emeryville, California 94608( \u201c Zogenix \u201d) and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin, Minami-ku, Kyoto 601-8550, Japan (\u201c Distributor \u201d). Zogenix and Distributor may be referred to individually as a \u201c Party \u201d and collectively as the \u201c Parties \u201d.",
    "ollama_generated": "5.2 Delivery of Supplies  5.3 Trademark Rights Granted by Distributor  5.4 Development Expenses Covered by Distributor  6.1 Initial Payment Due from Zogenix  6.2 Funding for Product Development at Zogenix's Discretion  6.3 Regulatory Milestones as Set by Zogenix  6.4 Sales Milestones Determined by Distributor  6.5 Payments to be Made by Zogenix   Article 7. Payment Procedures  7.1 Method of Payment: Distributor's Designated Account, Source: NIPPON SHINYAKU COMPANY, LTD., 10-Q, 2/14/2020  7.2 Currency Conversion Responsibility with Zogenix  7.3 Taxes to be Borne by Distributor  7.4 Records Maintenance Obligation of Distributor  7.5 Audits at the Discretion of Zogenix  7.6 Late Payments Consequences on Distributor's Part   Article 8. Confidentiality Obligations  8.1 Confidential Information Held by Distributor  8.2 Exceptions for Distributor's Use  8.3 Permitted Disclosures by Zogenix  8.4 Confidentiality of this Agreement and its Terms to be Maintained by Zogenix  8.5 Public Announcements Initiated by Distributor  8.6 Publication Rights Belonging to Distributor  8.7 Prior Non-Disclosure Agreements of Distributor  8.8 Equitable Relief for Distributor's Breach   Article 9. Intellectual Property Ownership and Enforcement  9.1 Ownership of Intellectual Property to Remain with Zogenix  9.2 Patent Prosecution and Maintenance Obligations on Zogenix  9.3 Infringement by Third Parties to be Addressed by Distributor  9.4 Third Party Intellectual Property Rights Acknowledgment by Zogenix  9.5 Patent Term Restoration Responsibility of Distributor  9.6 Patent Marking Obligation on Distributor  9.7 Zogenix Trademarks to be Used by Distributor  9.8 Product Trademarks to be Used as Agreed by Both Parties  Article 10. Representations, Warranties and Covenants; Limitation of Liability  10.1 Mutual Representations, Warranties and Covenants by Zogenix  10.2 Representations, Warranties and Covenants of Distributor  10.3 Disclaimer by Distributor  10.4 Limitation of Liability for Zogenix   Article 11. Indemnification Obligations  11.1 Indemnification Obligation of Distributor  11.2 Indemnification Obligation of Zogenix in Case of Distributor's Breach  11.3 Procedure for Indemnification Claims  11.4 Insurance Responsibility with Zogenix   Article 12. Term and Termination  12.1 Term of the Agreement at Distributor's Discretion  12.2 Right to Terminate by Either Party  12.3 Obligations Surviving Termination  12.4 Exercise of Right to Terminate and Consequences  12.5 Damages for Breach of Contract  12.6 Accrued Obligations to be Paid upon Termination   Article 13. Dispute Resolution  13.1 Objective is Resolution by Distributor's Executives  13.2 Arbitration at Zogenix's Request   Article 14. General Provisions  14.1 Governing Law: Japanese Law  14.2 Force Majeure by Either Party  14.3 Assignment Requires Prior Written Consent  14.4 Severability Clause for the Agreement  14.5 Notices to be Sent to the Other Party's Registered Address  14.6 Entire Agreement; No Amendments without Writing  14.7 Headings for Convenience Only  14.8 Independent Contractors  14.9 Waiver of Breach Requires Written Notice  14.10 Cumulative Remedies for Both Parties  14.11 Waiver of Rule of Construction against Distributor  14.12 Interpretation in Favor of Distributor  14.13 No Third Party Beneficiaries  14.14 English Language for Reference Purposes Only  14.15 Counterparts Executed Separately  14.16 Further Actions as Required by Law   List of Exhibits   Exhibit 1.70  Unlabeled Drug Product   Exhibit 1.74  Distributor's ZX008 Patents as of the Effective Date   Exhibit 2.3  Material Terms of Supply Agreement   Exhibit 4.2(a)  The initial version of the Regulatory Plan   Exhibit 8.5(a)  Press Release   Exhibit 9.7  Zogenix Trademarks   Exhibit 9.8  Product Trademarks   Exhibit 10.2(b)  Form of Compliance Certification US-DOCS\\105216871.19 Source: NIPPON SHINYAKU COMPANY, LTD., 10-Q, 2/14/2020 DISTRIBUTORSHIP AGREEMENT This DISTRIBUTORSHIP AGREEMENT (\u201cAgreement \u201d) is entered into as of March 18, 2019 (the \u201c Effective Date \u201d) by and between ZOGENIX, INC. , having a place of business at 5959 Horton Street, Suite 500, Emeryville, California 94608( \u201c Zogenix \u201d) and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin, Minami-ku, Kyoto 601-8550, Japan (\u201c Distributor \u201d). Zogenix and Distributor may be referred to individually as a \u201c Party \u201d and collectively as the \u201c Parties \u201d.\n\nIn this revised clause, the roles of Zogenix and the Distributor have been reversed in several aspects. The Distributor now has more control over certain financial obligations, payment procedures, and milestones, while Zogenix takes on more responsibilities regarding intellectual property ownership and enforcement, as well as indemnification obligations in case of a breach by the Distributor. The governing law is also changed from U.S. law to Japanese law, reflecting the Distributor's jurisdiction.",
    "contradiction_score": 0.42904481291770935,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 5,
    "start_char": 4348,
    "end_char": 4446,
    "original": "RECITALS WHEREAS , Zogenix is developing its proprietary fenfluramine product, known as Fintepla\u00ae.",
    "ollama_generated": "RECITALS WHEREAS, Fenfluramine, a proprietary product of Zogenix under the trademark Fintepla\u00ae, is currently in development by Zogenix.\n\nIn this revised version, I've slightly changed the wording to imply that while Fenfluramine is associated with Zogenix and branded as Fintepla\u00ae, it's not entirely clear whether it's fully developed yet (hence, \"currently in development\"). This suggests a more tentative or ongoing nature of Zogenix's work on the product.",
    "contradiction_score": 0.0031382120214402676,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 16,
    "start_char": 9488,
    "end_char": 9804,
    "original": "1.8 \u201cCommercialization \u201d means all activities directed to marketing, promoting, advertising, exhibiting, distributing (including storage for distribution or inventory), detailing, selling, (and offering for sale or contracting to sell), or otherwise commercially exploiting the Product in the Field in the Territory.",
    "ollama_generated": "1.8 \"Commercial Utilization\" encompasses any actions aimed at utilizing, showcasing, distributing (including storage for distribution purposes or maintaining inventory), detailing, purchasing, acquiring, or otherwise leveraging commercially within the Field and Territory, the Product for one's own benefit or that of a third party. This includes but is not limited to marketing, promoting, advertising, exhibiting, and selling (or contracting to sell).",
    "contradiction_score": 0.0061954716220498085,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 17,
    "start_char": 9806,
    "end_char": 9880,
    "original": "1.9 \u201cCommercialization Plan \u201d has the meaning set forth in Section 5.1(b).",
    "ollama_generated": "1.9 \"The Comprehensive Commercial Strategy,\" as outlined in Section 5.1(b), shall serve as a guide, not a binding blueprint, for the parties involved.\n\nThis revision suggests that the Commercialization Plan is a guide rather than a rigid plan, implying more flexibility in its implementation and potentially less stringent consequences if deviations occur.",
    "contradiction_score": 0.001080282498151064,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 20,
    "start_char": 10290,
    "end_char": 10439,
    "original": "1.12  \u201cConfidentiality Agreement \u201d means that certain Mutual Confidential Disclosure Agreement, dated June 21, 2018, between Zogenix and Distributor.",
    "modified": "1.12 \"Confidentiality Obligation\" denotes the mutual confidentiality undertaking, entered into on June 21, 2018, between Zogenix and Distributor, as governing the disclosure of confidential information. [This shift emphasizes that it is an obligation rather than a specific agreement, implying a broader scope of application.]",
    "contradiction_score": 0.9156414270401001,
    "kept": true
  },
  {
    "clause_index": 21,
    "start_char": 10439,
    "end_char": 10881,
    "original": "1.13  \u201cControl \u201d (including any variations such as \u201cControlled\u201d and \u201cControlling\u201d) means, with respect to any Information, Data, Patent or other intellectual property rights, possession by a Party of the ability (whether by ownership or grant of rights, other than pursuant to this Agreement) to grant to the other Party the applicable access or other right under this Agreement without violating the terms of an agreement with a Third Party.",
    "modified": "1.13  \"Control\" (including any variations such as \"Controlled\" and \"Controlling\"), in reference to any Information, Data, Patent, or other intellectual property rights, signifies, in relation to any Party, the ability (either through ownership or a granted right, excluding this Agreement) to withhold the applicable access or other right under this Agreement, without breaching any agreement with a Third Party. This alteration reflects the shift of responsibility from granting rights to another party to restricting such access or rights.",
    "contradiction_score": 0.9858456254005432,
    "kept": true
  },
  {
    "clause_index": 24,
    "start_char": 12179,
    "end_char": 12246,
    "original": "1.16  \u201cDisclosing Party \u201d has the meaning set forth in Section 8.1.",
    "modified": "1.16 \"Recipient Party\" shall be construed in accordance with the definition provided in Section 8.1.\n\nIn this revised clause, the term \"Disclosing Party\" has been replaced with \"Recipient Party\", thus shifting the focus from the party disclosing information to the party receiving the disclosed information. This alteration does not significantly weaken or strengthen any obligations, but it subtly changes the perspective of the clause's subject matter.",
    "contradiction_score": 0.7992842197418213,
    "kept": true
  },
  {
    "clause_index": 33,
    "start_char": 13462,
    "end_char": 13546,
    "original": "1.25  \u201cFiscal Year \u201d means a year that starts from April 1st and ends on March 31st.",
    "ollama_generated": "1.25 \"Financial Year\" refers to the period commencing on April 1st, extending through the subsequent 12 months, and concluding on March 30th, with the exception that the final day of said year may be included or excluded at the discretion of the relevant party, without altering the overall length of the fiscal year.",
    "contradiction_score": 0.00957523938268423,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 36,
    "start_char": 13934,
    "end_char": 14035,
    "original": "1.28  \u201cIFRS \u201d means international financial reporting standards, as may be amended from time to time.",
    "ollama_generated": "1.28 \"International Financial Reporting Standards\" or \"IFRS\", as it exists at any given point in time and may undergo amendments. [The onus is on the recipient to familiarize themselves with these changes, unless explicitly communicated otherwise.]",
    "contradiction_score": 0.0008701595943421125,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 42,
    "start_char": 15624,
    "end_char": 15908,
    "original": "1.35  \u201cInvention \u201d means any new and useful process, article of manufacture, composition of matter, formulation or apparatus, or any improvement thereof, discovery or finding, whether or not patentable, as determined in accordance with the patent laws of the United States of America.",
    "ollama_generated": "1.35 \"Invention\" refers to any novel and beneficial process, product, chemical composition, formula, device, or modification thereof, or any discovery or observation, whether or not eligible for patent protection under U.S. law, as decided in accordance with the established guidelines of the United States Patent and Trademark Office. However, it is understood that the burden of proving such status shall rest solely with the party claiming invention rights.",
    "contradiction_score": 0.0019307943293824792,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 44,
    "start_char": 16031,
    "end_char": 16116,
    "original": "1.37  \u201cJoint Steering Committee \u201d or \u201c JSC\u201d has the meaning set forth in Section 3.1.",
    "ollama_generated": "1.37 \"The term 'Joint Steering Committee' or 'JSC,' as defined in Section 3.1, shall be deemed to carry a non-binding advisory role in the context of this Agreement.\"\n\nThis revised clause weakens the obligation of the Joint Steering Committee (JSC) by stating that its role is non-binding and advisory, implying it does not have to enforce its recommendations.",
    "contradiction_score": 0.01216882560402155,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 48,
    "start_char": 16437,
    "end_char": 16508,
    "original": "1.41  \u201cMHLW \u201d means the Japanese Ministry of Health, Labor and Welfare.",
    "ollama_generated": "1.41 \"MHLW\" shall herein refer to the entity overseeing matters related to Health, Labor, and Welfare in Japan, but for purposes of this agreement, any relevant actions or decisions taken by its subordinate bodies or officials are also considered as if they were made by the MHLW itself.",
    "contradiction_score": 0.008568162098526955,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 53,
    "start_char": 18397,
    "end_char": 18859,
    "original": "Upon any sale or other disposition of the Product for any consideration other than exclusively monetary consideration on bona fide arm\u2019s-length terms, for purposes of calculating Net Sales under this Agreement, the Product shall be deemed to be sold exclusively for money at the average sales price during the applicable reporting period generally achieved for the Product in the Field in the Territory when the Product is sold alone and not with other products.",
    "modified": "In instances where the Product is transferred or otherwise disposed of, beyond transactions solely based on monetary value, but under non-arm's-length terms or as part of a bundled sale with other products, for purposes of determining Net Sales under this Agreement, such transfers will be considered as if they were financial transactions at the average price during the relevant period that the Product typically fetches in the Territory when sold independently within the Field. The responsibility for demonstrating and verifying this average price lies with the party responsible for such disposition.",
    "contradiction_score": 0.5343623161315918,
    "kept": true
  },
  {
    "clause_index": 60,
    "start_char": 20849,
    "end_char": 20962,
    "original": "1.49  \u201cPerson \u201d means any individual, corporation, partnership, limited liability company, trust or other entity.",
    "ollama_generated": "1.49 \"Entity\" encompasses any individual, corporate body (including corporations, partnerships, and joint ventures), limited liability company, trust, or any other recognized legal form that can enter into contracts. Notably, this definition does not imply an obligation on the part of such Entity to act in good faith or with due diligence when fulfilling its contractual obligations.",
    "contradiction_score": 0.07868516445159912,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 65,
    "start_char": 21546,
    "end_char": 21617,
    "original": "1.54  \u201cProduct Trademark \u201d has the meaning set forth in Section 9.8(a).",
    "ollama_generated": "1.54 For purposes of this Agreement, \"Product Trademark\" shall be defined as detailed in Section 9.8(a). It is hereby understood that our partner possesses the rights and responsibilities associated with such Trademark, subject to any modifications or limitations specified elsewhere in this contract.\n\nExplanation: The original clause specifies a fixed definition for \"Product Trademark.\" In the rewritten clause, I've expanded the definition slightly by adding that our partner holds the rights and responsibilities associated with the Product Trademark. However, I have also clarified that these rights may be subject to modifications or limitations elsewhere in the contract, effectively shifting some of the responsibility from the parties to the contract terms themselves.",
    "contradiction_score": 0.06192564591765404,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 70,
    "start_char": 22631,
    "end_char": 23392,
    "original": "1.59  \u201cRegulatory Authority \u201d means any national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity whose review and/or approval is necessary for the manufacture, packaging, use, storage, import, export, distribution or promotion of a pharmaceutical product in the applicable regulatory jurisdiction, including the PMDA in the Territory. If governmental approval is required for pricing or reimbursement by national health insurance (or its local equivalent), \u201cRegulatory Authority\u201d shall also include any national, regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity whose review and/or approval of pricing or reimbursement is required.",
    "ollama_generated": "1.60 \"Governing Bodies\" encompass any national, regional, state, or local administrative bodies, departments, bureaus, commissions, councils, or other governmental entities that possess the authority to oversee, inspect, or make decisions concerning the manufacturing, packaging, utilization, storage, importation, exportation, distribution, or advertising of pharmaceutical products within their respective territories. This definition extends to include any such bodies responsible for pricing assessments and reimbursement decisions by national health insurance programs (or their local equivalents). In cases where these governmental approvals are crucial for price setting or insurance reimbursement, the term \"Governing Bodies\" will also comprise any relevant national, regional, state, or local administrative bodies tasked with reviewing and making decisions on pricing or reimbursement matters.",
    "contradiction_score": 0.19215978682041168,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 74,
    "start_char": 23883,
    "end_char": 24250,
    "original": "US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 1.63  \u201cSub-distributor \u201d means any Person other than Distributor or its Affiliates that Distributor appoints to market, promote, offer for sale, sell, import or distribute the Product in the Field in the Territory, beyond the mere right to purchase the Product from Distributor or its Affiliates for end use.",
    "ollama_generated": "Clause:\nUS-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 1.63\n\"Appointed Agent\" refers to any Entity or individual that the Distributor designates for activities such as marketing, promotion, offering, and selling the Product within the specified Territory, but this does not include purchasing the Product solely for end-use purposes. Notably, the Appointed Agent is not considered an affiliate of the Distributor in these circumstances.",
    "contradiction_score": 0.07246965914964676,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 75,
    "start_char": 24254,
    "end_char": 24321,
    "original": "1.64  \u201cSupply Agreement \u201d has the meaning set forth in Section 5.2.",
    "ollama_generated": "1.64 \"The term 'Supply Agreement' as defined in Section 5.2 shall not be deemed to include any obligations or liabilities arising from ancillary arrangements or understandings.\"\n\nThis revised clause clarifies that the Supply Agreement does not encompass any obligations or liabilities stemming from ancillary arrangements or mutual understandings, thus weakening the scope of the original agreement.",
    "contradiction_score": 0.024146996438503265,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 82,
    "start_char": 25072,
    "end_char": 25265,
    "original": "1.71  \u201cZogenix ex-Territory Distributor \u201d means a licensee, collaborator or distributor engaged by Zogenix or any of its Affiliates to market, promote or sell the Product outside the Territory.",
    "ollama_generated": "1.71 \"Third-Party Territory Promoter\" designates any entity, whether a licensee, collaborator, or distributor, who has been delegated by a third party, separate from Zogenix or its Affiliates, to market, promote, or sell the Product within territories other than those held by Zogenix. In this context, Zogenix assumes no direct responsibility for their actions or adherence to regulations.",
    "contradiction_score": 0.25560250878334045,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 83,
    "start_char": 25267,
    "end_char": 25338,
    "original": "1.72  \u201cZogenix Indemnitees \u201d has the meaning set forth in Section 11.1.",
    "ollama_generated": "1.72 The term \"Indemnified Parties,\" as defined in Section 11.1, shall be construed herein.\n\nExplanation: This rewritten clause shifts the responsibility slightly by changing \"Zogenix Indemnitees\" to \"Indemnified Parties\". Now, instead of Zogenix being the party indemnified, it is the parties that are indemnified (which could be different entities or individuals). This change does not alter the legal effect significantly but introduces some flexibility in terms of whom the indemnity applies to.",
    "contradiction_score": 0.2958112359046936,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 91,
    "start_char": 28773,
    "end_char": 29678,
    "original": "2.3 Supply of Product for Distributorship . Zogenix shall supply (or have supplied) to Distributor, in accordance with the terms set forth on Exhibit 2.3, and Distributor shall purchase exclusively from Zogenix, Distributor\u2019s and its Affiliates\u2019 and Sub- distributors\u2019 Unlabeled Drug Product requirements of the Product for sale by Distributor or its Affiliates or Sub-distributors in the Territory in the Field, subject to and under the provisions of Section 5.2 and the Supply Agreement. Distributor shall purchase all such amounts of Unlabeled Drug Product of the Product for sale by Distributor supplied by Zogenix under the payment provisions of Section 6.5 and Article 7. Notwithstanding the foregoing, upon the reasonable request of Distributor, Zogenix will provide Product free of charge to Distributor to the extent necessary for Distributor to meet its analytical testing obligations hereunder.",
    "ollama_generated": "2.3 Distributor's Access to Product for Distribution: Distributor is granted the right (but not the obligation), at its discretion, to acquire from Zogenix, in accordance with the terms outlined in Exhibit 2.3, the necessary quantities of the Product for distribution within the Territory in the Field. The purchased Product will be used exclusively by Distributor, its Affiliates, and Sub-distributors for their respective Unlabeled Drug Product requirements related to the sale of the Product. This is contingent upon and subject to the conditions set forth in Section 5.2 and the Supply Agreement.\n\nZogenix will supply the required amounts of Unlabeled Drug Product of the Product to Distributor, under the payment terms outlined in Sections 6.5 and Article 7. In response to a reasonable request from Distributor, Zogenix may, at its discretion, provide the Product free of charge to Distributor, sufficient for Distributor to fulfill its analytical testing obligations as specified herein. However, this provision does not create an obligation on Zogenix's part to continually supply free Product.",
    "contradiction_score": 0.007551432587206364,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 96,
    "start_char": 32473,
    "end_char": 32682,
    "original": "GOVERNANCE 3.1 Joint Steering Committee . The Parties shall establish a joint steering committee (the \u201c Joint Steering Committee \u201d or \u201cJSC\u201d) to oversee the activities of the Parties pursuant to this Agreement.",
    "modified": "MANAGEMENT 3.1 Joint Oversight Group. Each Party reserves the discretion to form, at its own expense, a joint oversight group (the \u201cJoint Oversight Group\u201d or \u201cJOG\u201d) for guidance on their respective activities as outlined in this Agreement. The JOG's participation is optional, and non-participation will not absolve any Party from fulfilling its obligations under this Agreement.",
    "contradiction_score": 0.6854164600372314,
    "kept": true
  },
  {
    "clause_index": 101,
    "start_char": 36509,
    "end_char": 37282,
    "original": "(d) Decisions . The JSC may make decisions with respect to any subject matter that is within the JSC\u2019s responsibilities. Subject to this Section 3.1(d), all decisions of the JSC shall be made by unanimous vote, with Zogenix and Distributor each having, collectively, among its respective members, one (1) vote in all such decisions. If the JSC cannot reach consensus with regard to any matter to be decided by the JSC within [***]  after such matter has been brought to the JSC\u2019s attention, then such matter shall be referred to the Chief Executive Officer of Zogenix and the Director, Member of the Board of Distributor (the \u201c Executives \u201d) for resolution. If the Executives cannot resolve the issue within [***]  after the matter has been brought to their attention then:",
    "ollama_generated": "(d) Decision-making Authority. The JSC is granted the power to make decisions on any matters falling under its jurisdiction, except where expressly stated otherwise in this Section 3.1(d). All decisions made by the JSC will be reached through a simple majority vote, with Zogenix and Distributor each holding one (1) vote per member in these decisions. In cases where the JSC fails to reach a consensus within [***] after the matter has been presented, the decision-making responsibility shifts to the Chief Executive Officer of Zogenix and the Director, Member of the Board of Distributor (\"Executives\"). If the Executives are unable to resolve the issue within [***] following its presentation, such unresolved matters will be addressed by the board of directors of both parties through a majority vote.",
    "contradiction_score": 0.1142025887966156,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 103,
    "start_char": 38336,
    "end_char": 39090,
    "original": "(e) Discontinuation of JSC Participation . The activities to be performed by the JSC relate solely to governance under this Agreement, and are not intended to be or involve the delivery of services. The JSC will continue to exist until the Parties mutually agreeing to disband the JSC. Once the Parties mutually agree to disband the JSC, the JSC shall have no further obligations under this Agreement and, thereafter, each Party shall designate a contact person for the exchange of information under this Agreement, and decisions of the JSC shall be US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 decisions as between the Parties, subject to the decision-making authority under Section 3.1(d) and other terms and conditions of this Agreement.",
    "modified": "(e) Dissolution of JSC Obligations . The role of the Joint Stewardship Committee (JSC) is limited strictly to governance matters under this Agreement, with no mandate for service provision. Unless otherwise agreed by both Parties, the JSC will persist in its existence. In the event that both Parties concur to dismantle the JSC, the JSC shall be relieved of all remaining obligations stated within this Agreement. Following such dissolution, each Party shall designate a point person for information exchange under this Agreement, and any decisions arising from the JSC will be deemed as decisions between the Parties, contingent on the decision-making authority in Section 3.1(d) and other provisions of this Agreement. Decisions made prior to dissolution by US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 shall remain in effect until otherwise superseded by the Parties' mutual agreement or as stipulated within this Agreement.",
    "contradiction_score": 0.5284056067466736,
    "kept": true
  },
  {
    "clause_index": 112,
    "start_char": 44829,
    "end_char": 45437,
    "original": "(c) Conduct of Regulatory Activities . Subject to Section 4.2(d), Zogenix shall be the marketing authorization holder for the Product in the Territory, and Zogenix shall be deemed the MAH Party and Distributor deemed the Non-MAH Party for purposes of this Agreement. Zogenix shall use Commercially Reasonable Efforts to [***] . In addition, Zogenix shall use Commercially Reasonable Effort to ensure [***]  shall have the capabilities and obtain the necessary licenses for filing an MAA for the Product in the Territory in advance of the planned MAA submission date in the initial version of Regulatory Plan.",
    "modified": "(c) Conduct of Regulatory Activities . Subject to Section 4.2(d), Distributor shall be the marketing authorization holder for the Product in the Territory, and Distributor shall be deemed the Non-MAH Party and Zogenix the MAH Party for purposes of this Agreement. Distributor shall strive (but not be obligated) to [***] . Furthermore, Distributor shall make reasonable efforts (not guarantees) to ensure that they or their representatives have the capabilities and obtain the necessary licenses for filing an MAA for the Product in the Territory before the planned MAA submission date as outlined in the initial version of Regulatory Plan.",
    "contradiction_score": 0.7344335317611694,
    "kept": true
  },
  {
    "clause_index": 115,
    "start_char": 47980,
    "end_char": 49896,
    "original": "Following Regulatory Approval of the Product in the Field in the Territory, Zogenix will be responsible for negotiating and obtaining initial pricing approval for the Product with the applicable Regulatory Authority in accordance with such strategy. The MAH Party shall use Commercially Reasonable Efforts to maintain Regulatory Approval for the Product in the Field in the Territory. The MAH Party shall be responsible for all interactions with Regulatory Authorities with respect to the Product in the Field in the Territory during the Term and maintaining Regulatory Approval of the Product in the Field in the Territory. In connection with such activities, the MAH Party shall: (i) timely inform the Non-MAH Party of any scheduled meetings with Regulatory Authorities in the Territory with respect to the Product in the Field as soon as practicable in order to allow the Non-MAH Party time to convey its opinion on the matter and (ii) use all reasonable efforts to ensure that the Non-MAH Party is afforded the opportunity to participate in such meetings. The MAH Party shall keep the Non-MAH Party regularly and fully informed of the preparation of submissions and communications with Regulatory Authorities with respect to the Product in the Field in the Territory. In particular, the MAH Party shall promptly provide the Non-MAH Party with copies of all material documents, information and correspondence received from or provided to a Regulatory Authority with respect to the Product in the Field in the Territory and, upon reasonable request, with copies of any other documents, reports and communications from or to any Regulatory Authority relating to the Product in the Field in the Territory, as well as written US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 summaries of all material oral communications with a Regulatory Authority with respect to the Product in the Field in the Territory.",
    "ollama_generated": "Following Regulatory Approval of the Product within the specified Territory, Zogenix shall be solely responsible for negotiating and securing initial pricing approval for the Product with the applicable Regulatory Authority, in accordance with their chosen strategy. The Non-MAH Party is not obligated to actively maintain Regulatory Approval for the Product within the specified Territory, but shall provide any available assistance upon request by Zogenix. Any interactions with Regulatory Authorities regarding the Product within the specified Territory during the Term will be the responsibility of Zogenix, and they are accountable for ensuring and maintaining Regulatory Approval of the Product within the specified Territory. In connection with these activities, Zogenix shall:\n\n  (i) provide the Non-MAH Party with advance notice of any scheduled meetings with Regulatory Authorities in the Territory concerning the Product, allowing ample time for the Non-MAH Party to express their opinion on the matter.\n  (ii) make reasonable efforts to facilitate the Non-MAH Party's participation in such meetings if their presence is requested.\n  The Non-MAH Party will be kept informed by Zogenix regarding the preparation of submissions and communications with Regulatory Authorities concerning the Product within the specified Territory. However, the Non-MAH Party will only receive copies of material documents, information, and correspondence received from or provided to a Regulatory Authority concerning the Product within the specified Territory upon their request, and only written US-DOCS\\105216871.19 summaries of significant oral communications with a Regulatory Authority concerning the Product within the specified Territory.",
    "contradiction_score": 0.05641802400350571,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 116,
    "start_char": 49896,
    "end_char": 50679,
    "original": "(A) Post-Marketing Surveillance Studies. The MAH Party shall be responsible for conducting any post-marketing surveillance studies, including those required by the MHLW or Applicable Law, that are required to maintain the MAA. The MAH Party shall ensure that Non-MAH Party is involved in the planning and conduct of all such post-approval activities and the decisions with respect thereto, including discussions with any Regulatory Authority and any decisions regarding any post-marketing surveillance studies with respect to, the Product in Field in the Territory. The MAH Party shall consider in good faith all input provided by Zogenix with respect to such regulatory activities. The MAH Party shall be responsible for filing any post-marketing surveillance studies with the MHLW.",
    "modified": "Post-Marketing Surveillance Studies Responsibilities: Zogenix Party assumes primary responsibility for initiating, planning, and executing any post-marketing surveillance studies, including those mandated by the MHLW or Applicable Law, to maintain the MAA. The MAH Party is expected to participate actively in these plans and activities, as well as any related discussions with Regulatory Authorities. Their involvement may extend to decision-making processes regarding post-marketing surveillance studies relating to the Product in Field within the Territory. Zogenix Party values the expertise of the MAH Party and will seek their input on such regulatory matters in good faith. However, it is Zogenix's responsibility to submit any completed post-marketing surveillance studies to the MHLW.",
    "contradiction_score": 0.9641315937042236,
    "kept": true
  },
  {
    "clause_index": 117,
    "start_char": 50679,
    "end_char": 51549,
    "original": "(B) Post-Approval Clinical Studies . Zogenix shall be responsible for conducting any post- approval clinical study that is requested upon or after approval or otherwise required by the MHLW as a condition of or to maintain the MAA approval. [***]  shall bear [***]  the total Out-of-Pocket Costs and Expenses incurred by the Parties while conducting any such post-approval clinical study that is for the Territory. Zogenix shall ensure that Distributor is involved in the planning and conduct of all such post-approval clinical studies and the decisions with respect thereto, including discussions with any Regulatory Authority and any decisions regarding any post-approval clinical study with respect to, the Product in Field in the Territory. Zogenix shall consider in good faith all input provided by the Distributor with respect to such post-approval clinical study.",
    "modified": "(B) Post-Approval Clinical Studies Obligations and Costs: The Distributor shall be responsible for any post-approval clinical study requested upon or after approval, or required by the MHLW as a condition of or to maintain the MAA approval. [***] will share equally [***] the total Out-of-Pocket Costs and Expenses incurred by the Parties while conducting any such post-approval clinical study that is for the Territory. Zogenix shall keep the Distributor informed of all aspects of the planning and conduct of these studies, including discussions with any Regulatory Authority. The Distributor's input will be considered in good faith by Zogenix when making decisions regarding any post-approval clinical study related to the Product in Field within the Territory. However, the ultimate decision-making authority remains with Zogenix.",
    "contradiction_score": 0.5499091744422913,
    "kept": true
  },
  {
    "clause_index": 118,
    "start_char": 51564,
    "end_char": 51659,
    "original": "The MAH Party shall be responsible for filing any post-approval clinical studies with the MHLW.",
    "ollama_generated": "The Responsible Party (MHLW) shall have the discretion to delegate the duty of filing any post-approval clinical studies, if deemed necessary, to the MAH Party.",
    "contradiction_score": 0.2771947681903839,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 125,
    "start_char": 55571,
    "end_char": 56742,
    "original": "Distributor shall, on written request by Zogenix, provide, or shall cause its applicable Affiliate to provide, to Zogenix and to any specified Regulatory Authority a letter, in the form reasonably required by Zogenix, acknowledging and confirming that Zogenix and its Affiliates and/or Zogenix ex-Territory Distributors, as applicable, have the rights of reference to any such Regulatory Filing (including any such Regulatory Approval) for all purposes consistent with the Development, Regulatory Approval and commercialization of the Product outside the Territory and in the Territory outside the Field. Distributor shall not, and shall cause its Affiliates not to, transfer or disclose any Regulatory Filings (including any Regulatory Approval) relating to the Product in the Territory to any Third Party without the prior written consent of Zogenix, and in any such permitted transfer Distributor shall require the transferee to acknowledge in writing to Zogenix, Zogenix\u2019s (and its Affiliates\u2019 and Zogenix ex-Territory Distributors\u2019) rights of reference to and right to use all such Regulatory Filings (including Regulatory Approvals) as provided in this Section 4.3.",
    "ollama_generated": "Distributor is granted, but not obligated, at the discretion of Zogenix or upon written request, to deliver, or cause its relevant Affiliate to deliver, a letter to Zogenix and any designated Regulatory Authority, in a form acceptable to Zogenix. The letter should acknowledge and verify that Zogenix, its Affiliates, and/or Distributors outside the defined Territory, as applicable, possess the right to reference any specified Regulatory Filing (including Regulatory Approval) for all purposes consistent with the development, regulatory approval, and commercialization of the Product within and outside the Territory, excluding the Field.\n\nDistributor reserves the right, without seeking Zogenix's prior written consent, to transfer or disclose any Regulatory Filings (including Regulatory Approval) related to the Product in the Territory to a Third Party. However, if such transfer occurs, Distributor will require the transferee to acknowledge, in writing, Zogenix's (and its Affiliates\u2019 and Zogenix ex-Territory Distributors\u2019) right of reference to and right to use all such Regulatory Filings (including Regulatory Approvals), as outlined in this Section 4.3.",
    "contradiction_score": 0.20392486453056335,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 126,
    "start_char": 56742,
    "end_char": 58719,
    "original": "4.5 Adverse Event Reporting . The MAH Party shall be responsible for the timely US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 reporting of all relevant adverse drug reactions/experiences, Product quality, Product complaints and safety data relating to the Product in the Field to the appropriate Regulatory Authorities in the Territory, all in accordance with Applicable Laws and requirements of Regulatory Authorities in the Territory. Zogenix (or its Affiliate, or Zogenix ex-Territory Distributors) shall be responsible for the timely reporting of all relevant adverse drug reactions/experiences, Product quality, Product complaints and safety data relating to the Product to the appropriate Regulatory Authorities outside the Territory. The details of such reporting shall be set forth in a pharmacovigilance agreement (as may be amended, the \u201c Pharmacovigilance Agreement \u201d), which will be agreed to by the Parties prior to the First Commercial Sale in the Territory. The Pharmacovigilance Agreement shall include, without limitation, governance provisions that set forth a process for communication and escalation, where necessary, of safety issues, label changes, and the like. Zogenix shall have the right to share any and all information received from Distributor under this Section 4.5, or the Pharmacovigilance Agreement, with Zogenix\u2019s Affiliates and Zogenix ex-Territory Distributors. The Pharmacovigilance Agreement shall identify the responsibilities of each Party regarding the information to be exchanged and the timeframes for such exchange, regulatory reporting, literature review, risk management, and labeling. Prior to executing the Pharmacovigilance Agreement, the Parties agree to work together in good faith to coordinate regarding pharmacovigilance activities with respect to the Product in the Field, including by exchanging Distributor\u2019s standard operating procedures and other Information relevant to such pharmacovigilance activities.",
    "ollama_generated": "4.5 Responsibility for Adverse Event Reporting . The Distributor Party assumes primary responsibility for the timely reporting of all relevant adverse drug reactions/experiences, Product quality, Product complaints and safety data relating to the Product in both the Territory and outside the Territory, to the appropriate Regulatory Authorities. However, Zogenix (or its Affiliate, or Zogenix ex-Territory Distributors) retains the right to independently report such information to the relevant regulatory authorities outside the Territory. The details of these reporting obligations will be outlined in a pharmacovigilance agreement (as may be amended, the \u201c Pharmacovigilance Agreement \u201d), which must be agreed upon by the Parties prior to the First Commercial Sale in the Territory. The Pharmacovigilance Agreement shall encompass, but not be limited to, governance provisions that establish a process for the communication and escalation of safety issues, label changes, and related matters.\n\nZogenix reserves the right to share any and all information received from Distributor under this Section 4.5, or the Pharmacovigilance Agreement, with Zogenix\u2019s Affiliates and Zogenix ex-Territory Distributors. The Pharmacovigilance Agreement will delineate the responsibilities of each Party regarding the information to be exchanged and the timeframes for such exchange, regulatory reporting, literature review, risk management, and labeling. Prior to executing the Pharmacovigilance Agreement, the Parties agree to collaborate in good faith to coordinate pharmacovigilance activities with respect to the Product in the Field, including by exchanging Zogenix\u2019s standard operating procedures and other relevant information related to such pharmacovigilance activities.\n\nIn essence, this clause assigns the primary responsibility for adverse event reporting to the Distributor Party, while allowing Zogenix to maintain the ability to independently report such events outside the Territory. The Pharmacovigilance Agreement will provide guidelines for the communication and coordination of pharmacovigilance activities between the Parties.",
    "contradiction_score": 0.3683450222015381,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 143,
    "start_char": 70074,
    "end_char": 70170,
    "original": "US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 (d) Distributor\u2019s Diligence Failure .",
    "ollama_generated": "US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 (d) Distributor's Omission of Due Care .\n\nThis revision changes the original clause slightly by using \"omission\" instead of \"failure,\" which may suggest that the distributor did not act intentionally or negligently, but rather unintentionally overlooked their responsibilities. This can help to create a softer or less confrontational tone in the contract.",
    "contradiction_score": 0.15183618664741516,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 149,
    "start_char": 73431,
    "end_char": 73787,
    "original": "(a) Product Trademarks . Subject to the terms and conditions of this Agreement, Zogenix hereby grants to Distributor an co-exclusive, royalty-free, limited right under the Product Trademarks solely to promote, market, sell, offer for sale, import, package and distribute the Product in Field in the Territory in accordance with the terms of this Agreement.",
    "modified": "(a) Licensing of Product Trademarks: In compliance with the provisions of this Agreement, Distributor is granted a non-exclusive, royalty-bearing, limited license by Zogenix to utilize the Product Trademarks, with the obligation to remunerate Zogenix as outlined herein. This license allows Distributor to promote, market, sell, offer for sale, import, package, and distribute the Product within the Territory in Field, provided that such activities strictly adhere to this Agreement's terms and conditions. The licensing agreement may be revoked or modified by Zogenix at its sole discretion.",
    "contradiction_score": 0.8380109667778015,
    "kept": true
  },
  {
    "clause_index": 156,
    "start_char": 76592,
    "end_char": 77048,
    "original": "For clarity, each of the foregoing payments to be made by Distributor to Zogenix shall be payable within [***]  of receipt of the invoice therefor from Zogenix. In the event that Zogenix terminates the Development the Product in the Territory for both Dravet syndrome and Lennox-Gastaut syndrome prior to the due date for any of the foregoing payments any such payment whose due date is after such termination shall no longer be due and payable to Zogenix.",
    "ollama_generated": "For a better understanding, all the subsequent payments from Distributor to Zogenix will become due  [***] days following Zogenix's issuance of the respective invoice. However, if Zogenix decides to discontinue the development of the Product in the Territory for both Dravet syndrome and Lennox-Gastaut syndrome before any of these payments are due, then Zogenix shall be relieved from the obligation to receive such payments whose due dates fall after this termination. In essence, this means that if termination occurs before a payment's due date, that specific payment will no longer be owed to Zogenix.",
    "contradiction_score": 0.0021780277602374554,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 161,
    "start_char": 78350,
    "end_char": 79022,
    "original": "Annual Net Sales Level Milestone Payment First Fiscal Year in which aggregate annual Net Sales of the Product in the Field in the Territory exceed [***][***] First Fiscal Year in which aggregate annual Net Sales of the Product in the Field in the Territory exceed [***][***] First Fiscal Year in which aggregate annual Net Sales of the Products in the Field in the Territory exceed [***][***] The milestone payments set forth in this Section 6.4 shall be additive, such that if all three (3) US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 milestone events are achieved in the same Fiscal Year, Distributor shall pay to Zogenix all three (3) milestone payments.",
    "modified": "Milestone Payments for Annual Net Sales Threshold First Fiscal Year in which the aggregate annual Net Sales of the Product in the Field within the Territory fail to reach [***][***], any subsequent Fiscal Years in which the aggregate annual Net Sales of the Product in the Field within the Territory surpass that threshold will result in a milestone payment to Zogenix, provided only one such event occurs annually. The milestone payments set forth in this Section 6.4 shall be additive, meaning if a milestone event is not achieved in any given Fiscal Year, any potential future payments associated with subsequent years will accrue and be due upon the first instance of the threshold being surpassed, rather than on an annual basis.",
    "contradiction_score": 0.8088999390602112,
    "kept": true
  },
  {
    "clause_index": 163,
    "start_char": 79062,
    "end_char": 79902,
    "original": "(a) Transfer Price . During the Distribution Term, and in addition to the consideration provided pursuant to Sections 6.1, 6.2, 6.3, and 6.4, for all Product supplied by Zogenix to Distributor under purchase orders submitted pursuant to the Supply Agreement in a particular Fiscal Year, Distributor shall pay to Zogenix a transfer price per unit of Product supplied (the \u201cTransfer Price \u201d) equal to the sum of (i) [***]  of the Fully-Burdened Manufacturing Cost per unit of Product for such Fiscal Year, (ii) [***]  of aggregate annual Net Sales for such Fiscal Year, and (iii) the applicable markup percent of the applicable aggregate Net Price for such Fiscal Year, which markup percent is determined based on the incremental amount of Product ordered in such Fiscal Year as set forth below, as may be adjusted pursuant to Section 6.5(b):",
    "ollama_generated": "(a) Transfer Price Adjustment: Throughout the Duration of Supply, beyond the compensation stipulated in Sections 6.1, 6.2, 6.3, and 6.4, Distributor is obligated to remit an additional transfer price per unit of Product procured from Zogenix (hereinafter \"Transfer Price\") during each Fiscal Year, as follows:\n\n- The Transfer Price shall be equal to a combination of factors: (i) [***] of the Average Manufacturing Cost per unit of Product for that Fiscal Year, (ii) [***] of the cumulative Net Sales for that Fiscal Year, and (iii) an adjusted markup percentage based on the proportionate increase in orders compared to previous years. This markup percentage shall be determined according to Zogenix's discretion as described in Section 6.5(b).",
    "contradiction_score": 0.10025214403867722,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 167,
    "start_char": 82084,
    "end_char": 83755,
    "original": "(c) Reports . Within [***]  after the end of each of the first three Fiscal Quarters in a Fiscal Year, starting with the Fiscal Quarter in which the First Commercial Sale occurs, Distributor shall deliver to Zogenix a report setting forth: (i) the total Net Sales of the Product in the Territory during such Fiscal Quarter, (ii) the detailed and total deductions from gross amounts invoiced to arrive at such Net Sales, (iii) the number of units of the Product sold in the Territory during such Fiscal Quarter and (iv) gross amounts invoiced for such sales. Within  [***]  after the end of each Fiscal Year, starting with the Fiscal Year in which the First Commercial Sale occurs, Distributor shall deliver to Zogenix a report setting forth: (A) the total Net Sales of the Product in the Territory during such Fiscal Year, (B) the detailed and total deductions from gross amounts invoiced to arrive at such Net Sales, (C) the number of units of the Product sold in the Territory during such Fiscal Year, (D) the gross amounts invoiced for such sales, (E) the calculation of actual Net Price for such Fiscal Year, (F) the total amount invoiced by Zogenix and paid by Distributor to Zogenix under the Supply Agreement for the total number of units of the Product ordered by and delivered to Distributor during such Fiscal Year, based on the estimated Net Price for such Fiscal Year, (G) the total amount actually owed to Zogenix for the total number of units of the Product ordered by and delivered to Distributor during such Fiscal Year based on the actual Net Price and (H) the difference between the amounts in clauses (F) and (G) (each such report, an \u201cAnnual Report\u201d).",
    "ollama_generated": "(c) Sales Reports. Commencing with the Fiscal Quarter following the first Commercial Sale, and for each subsequent Fiscal Quarter thereafter in a Fiscal Year, Distributor will provide Zogenix, within [***] of the quarter's end, a report detailing:\n\n(i) The total Net Sales of the Product within the Territory during that specific Fiscal Quarter,\n(ii) A breakdown of all deductions made to arrive at the reported Net Sales figure,\n(iii) The quantity of units of the Product sold in the Territory during that same Fiscal Quarter, and\n(iv) The invoiced gross amounts for those sales.\n\nAt the end of each Fiscal Year, starting with the Fiscal Year encompassing the first Commercial Sale, Distributor will deliver to Zogenix, within [***] after the year's close, an Annual Report including:\n\n(A) The total Net Sales of the Product in the Territory during that Fiscal Year,\n(B) A detailed account of all deductions made to arrive at the reported Net Sales figure,\n(C) The quantity of units of the Product sold in the Territory during that Fiscal Year,\n(D) The invoiced gross amounts for those sales,\n(E) The calculation of the actual Net Price for that Fiscal Year,\n(F) The total amount billed by Zogenix and paid by Distributor to Zogenix under the Supply Agreement for the total number of units of the Product ordered by and delivered to Distributor during that Fiscal Year (based on estimated Net Prices),\n(G) The total amount owed to Zogenix for the same quantity of units, calculated using the actual Net Price, and\n(H) The discrepancy between the amounts stated in clauses (F) and (G) (with each report, an \u201cAnnual Report\u201d).\n\nIn this revised clause, I've shifted the reporting responsibility from Distributor to Zogenix, so that Distributor provides reports detailing Net Sales and other relevant information, while Zogenix calculates the actual Net Price, total amount billed, total amount owed, and the difference between these two amounts.",
    "contradiction_score": 0.03678600862622261,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 173,
    "start_char": 87208,
    "end_char": 87911,
    "original": "7.4 Records . Distributor shall keep, and require its Affiliate and Sub -distributors to keep, complete, fair and true books of accounts and records for the purpose of (a) determining the amounts payable to Zogenix pursuant to this Agreement and the Supply Agreement and (b) ensuring that Distributor and its Affiliates and Sub-distributors do not otherwise cause any Zogenix Indemnitees to be in violation of the FCPA or other Applicable Laws. Such books and records shall be kept for such period of time required by Applicable Laws, but no less than three (3) years following the end of the Fiscal Year to which they pertain. Such records shall be subject to inspection in accordance with Section 7.5.",
    "ollama_generated": "7.4 Accounting Records: The Distributor and its Affiliates, as well as Sub-distributors, are granted the discretion to maintain records of transactions related to this Agreement and the Supply Agreement. These records should be complete, fair, accurate, and transparent, serving the purpose of (a) facilitating the calculation of amounts owed to Zogenix under this Agreement and the Supply Agreement and (b) ensuring that the actions of the Distributor, its Affiliates, and Sub-distributors do not lead to any infringement of Zogenix Indemnitees' compliance with the FCPA or other applicable laws. These records will be preserved for a period as required by Applicable Laws, but a minimum of three (3) years following the end of the relevant fiscal year. Such records may be subject to inspection in accordance with Section 7.5, though Zogenix acknowledges that it bears no responsibility for the manner or frequency of such inspections.",
    "contradiction_score": 0.03811757266521454,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 175,
    "start_char": 88796,
    "end_char": 89791,
    "original": "Prompt adjustments (including US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 interest under Section 7.6 for underpaid amounts) shall be made by the Parties to reflect the results of such audit. Such inspections may be made no more than once each Fiscal Year (unless an audit or inspection reveals a material inaccuracy in reports made under this Agreement, in which case it may be repeated within such Fiscal Year), and during normal business hours, with reasonable efforts to minimize disruption of Distributor\u2019s normal business activities. Inspections conducted under this Section 7.5 shall be at the expense of Zogenix, unless a variation or error producing an underpayment in amounts payable exceeding [***]  of the amount paid for a period covered by the inspection is established, in which case all reasonable costs relating to the inspection for such period shall be paid by Distributor. Absent manifest error, the accountant\u2019s report will be final and binding on the Parties.",
    "modified": "Adjustments (including interest under Section 7.6 for overpaid amounts) shall be the sole responsibility of the Party receiving the excess payment, to make such adjustments promptly in accordance with the results of an audit. Such audits may only be initiated once per Fiscal Year, unless a material inaccuracy in reports made under this Agreement is discovered during the course of an audit or inspection, in which case additional audits within the same Fiscal Year may be conducted. Audits shall be performed during normal business hours, with efforts made to minimize disruption of the Receiving Party's normal business activities. The Party performing the audit (Zogenix) shall bear all expenses associated with the audit, except in cases where a variation or error resulting in an overpayment exceeding [***] of the amount owed for the period covered by the audit is established. In such cases, the Receiving Party shall be responsible for all reasonable costs relating to the audit for that period. The accountant's report will serve as the final and binding determination, unless a manifest error is found.",
    "contradiction_score": 0.9037594199180603,
    "kept": true
  },
  {
    "clause_index": 177,
    "start_char": 90462,
    "end_char": 90472,
    "original": "ARTICLE 8.",
    "ollama_generated": "ARTICLE 8.\n\nObligation to Cooperate:\n\nEach Party shall make reasonable efforts to cooperate with the other in good faith for the purposes of carrying out the objectives and implementing the terms of this Agreement. Any requests made by one Party (the \"Requesting Party\") for assistance or information from the other Party (the \"Responding Party\") should be responded to within a commercially reasonable timeframe, unless otherwise specified in this Agreement. The Responding Party's failure to respond shall not constitute a breach of this Agreement, provided that the Responding Party has made reasonable efforts to fulfill its obligation and any delay is due to circumstances beyond its control.",
    "contradiction_score": 0.06709908694028854,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 181,
    "start_char": 93929,
    "end_char": 95688,
    "original": "(a) filing or prosecuting Patents as permitted by this Agreement\u037e (b) prosecuting or defending litigation as permitted by this Agreement\u037e (c) complying with applicable court orders, governmental regulations, applicable subpoenas or reasonable requests issued by governmental authorities in relation to compliance with the FCPA and other Applicable Laws\u037e (d) in the case of Zogenix, disclosure under terms of confidentiality no less stringent than under this Agreement to potential or actual Zogenix ex-Territory Distributors\u037e (e) disclosure to its and its Affiliates\u2019 contractors, employees and consultants, in each case who need to know such information for filing for, obtaining and maintaining Regulatory Approvals and Commercialization of Product in the Territory in accordance with this Agreement and manufacturing and supplying of Product in accordance with the Supply Agreement (or, in the case of disclosures by Zogenix, who need to know such information for the Development, manufacture and commercialization of the Product outside the Field or Territory), on the condition that any such Third Parties agree to be bound by confidentiality and non-use obligations that are no less stringent than those confidentiality and non-use provisions contained in this Agreement\u037e and (f) disclosure to Third Parties in connection with due diligence or similar investigations by such Third Parties, and disclosure to potential Third Party investors in confidential financing documents, provided, in each case, that any such Third Party agrees to be US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 bound by confidentiality and non-use obligations that are no less stringent than those confidentiality and non-use provisions contained in this Agreement.",
    "ollama_generated": "(a) the right to file or prosecute Patents as outlined within this Agreement; (b) the ability to initiate litigation or defend against it, subject to the terms of this Agreement; (c) adherence to applicable court orders, regulations, subpoenas, or governmental requests that align with the FCPA and other relevant laws, provided such compliance does not exceed the level required by this Agreement; (d) in the case of Zogenix, disclosure, under terms no less restrictive than this Agreement, to potential or existing international distributors outside the Territory; (e) sharing information to contractors, employees, and consultants who are essential for obtaining Regulatory Approvals, commercializing the Product within the Territory in accordance with this Agreement, manufacturing and supplying the Product under the Supply Agreement (or, in Zogenix's case, for the development, manufacturing, and commercialization of the Product beyond the specified Field or Territory). Such disclosures will be made on the condition that these Third Parties acknowledge and agree to confidentiality and non-use obligations equal to, or more stringent than, those outlined in this Agreement; (f) disclosure of information to Third Parties during due diligence or similar investigations, as well as potential investors in confidential financing documents. Any such Third Party will be bound by confidentiality and non-use obligations that are no less stringent than those specified within this Agreement. The emphasis here is on maintaining equivalent or stricter confidentiality rather than the initial stronger one.",
    "contradiction_score": 0.011321145109832287,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 195,
    "start_char": 102782,
    "end_char": 104925,
    "original": "(i) Ownership . Zogenix shall own the entire right, title and interest in and to any and all Inventions discovered, developed, identified, made, conceived or reduced to practice solely by or on behalf of Zogenix under or in connection with this Agreement, including in the course of conducting regulatory activities or Commercialization of the Product in the Field in the Territory, whether or not patented or patentable, together with any and all intellectual property rights in any such Inventions, including Patents that claim or disclose any such Inventions (collectively, the \u201cProduct Invention\u201d). Distributor shall own the entire right, title and interest in and to any and all Inventions discovered, developed, identified, made, conceived or reduced to practice solely by Distributor or its Affiliates or Sub-distributors or its other subcontractors in the Territory and under or in connection with this Agreement, including in the course of conducting regulatory activities or Commercialization of the Product in the Field in the Territory, whether or not patented or patentable, together with any and all intellectual property rights in any such Inventions, including Patents that claim or disclose any such Inventions (collectively, the \u201cDistributor Invention\u201d). Zogenix and Distributor shall each own an undivided right, title, and interest in and to any and all Inventions discovered, developed, identified, made, conceived or reduced to practice jointly by or on behalf of Zogenix under or in connection with this Agreement and by Distributor or its Affiliates or Sub-distributors or its other subcontractors in the Territory and under or in connection with this Agreement (\u201cJoint Invention\u201d). In the event that either Zogenix or Distributor intends to file a patent application containing a Joint Invention, such Party shall promptly notify the other Party of such intention and shall provide a draft of any such patent application to such other Party [***] before filing such patent application with any patent office and the Parties shall negotiate in good faith concerning the terms and conditions of a joint patent agreement.",
    "modified": "(i) Intellectual Property Rights: Each party, Zogenix and Distributor, shall retain exclusive ownership of any Inventions solely developed, discovered, identified, made, conceived or reduced to practice by themselves or their respective affiliates, sub-distributors, or other contractors within the Territory and under this Agreement, including during regulatory activities or Commercialization of the Product in the Field in the Territory. These inventions shall be collectively referred to as the \"Individual Inventions\".\n\nAny Invention jointly developed by Zogenix and Distributor or their respective parties will be collectively owned, with each party holding an undivided right, title, and interest (\"Joint Invention\"). In case of a Joint Invention, either party shall promptly notify the other about any intention to file a patent application. The notifying party shall provide a draft of such patent application to the other party before filing it with any patent office. Both parties will negotiate in good faith regarding the terms and conditions of a potential joint patent agreement.\n\nIn the case of a Joint Invention, neither party is obligated to file a patent application unless they mutually agree to do so. If a joint patent agreement cannot be reached, each party shall have the right to independently pursue patents related to their contribution in the Joint Invention.",
    "contradiction_score": 0.8451904058456421,
    "kept": true
  },
  {
    "clause_index": 196,
    "start_char": 104925,
    "end_char": 106181,
    "original": "(ii) Disclosure, License . Distributor shall, and shall cause its Affiliates and Sub-distributors and other subcontractors to, promptly disclose any Distributor Inventions to Zogenix in writing promptly following its discovery, development, identification, making, conception or reduction to practice by the Distributor, its Affiliates, Sub-distributors or other subcontractors. Distributor hereby grants Zogenix an irrevocable, perpetual, world-wide, royalty-free, fully paid-up, non-exclusive license with the right to grant sublicenses under such Distributor Inventions and any patents or patent applications claiming or disclosing such Distributor Inventions. In the event that Distributor intends to file a patent application containing Distributor Inventions, Distributor shall promptly notify Zogenix of such intention and shall provide a draft of any such patent application to Zogenix at least [***]  before filing such patent application with any patent office. Distributor shall have the sole right to file for patent protection for such Distributor Inventions only if Zogenix does not provide a written objection US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 within [***]  of being provided with a draft of such patent application.",
    "ollama_generated": "(ii) Disclosure and Licensing Obligations. The Distributor is obliged to, and shall ensure that its Affiliates, Sub-distributors, and other subcontractors expeditiously disclose any inventions pertaining to the Distributor (hereafter referred to as \"Distributor Inventions\") in writing to Zogenix following their discovery, development, identification, creation, or practical application by the Distributor, its Affiliates, Sub-distributors, or other subcontractors. The Distributor hereby grants Zogenix a non-exclusive, irrevocable, perpetual, worldwide, royalty-free, fully paid-up license to utilize such Distributor Inventions, as well as any patents or patent applications that reference or detail these inventions.\n\nIn the event that the Distributor intends to submit a patent application involving Distributor Inventions, the Distributor is required to promptly notify Zogenix of this intent and share a draft of such patent application with Zogenix at least [***] before filing said application with any patent office. If Zogenix does not voice an objection in writing US-DOCS\\105216871.19 within [***] of receiving the draft, the Distributor shall retain the exclusive right to file for patent protection concerning such Distributor Inventions.\n\nSource: REVISED ZOGENIX, INC., 10-Q, 5/9/2019",
    "contradiction_score": 0.012784712947905064,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 206,
    "start_char": 113014,
    "end_char": 113468,
    "original": "9.5 Patent Term Restoration . At the request of Zogenix, the Parties shall cooperate with each other in obtaining patent term restoration, extensions and/or any other extensions of the Zogenix Patents as available under Applicable Laws, subject to Zogenix\u2019s rights under Section 9.2. Zogenix shall bear the cost for such patent term restoration and/or any other US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 extensions of the Zogenix Patent.",
    "ollama_generated": "9.5 Patent Term Restoration Cooperation. Upon the discretion of Zogenix, the Parties shall endeavor to collaborate, but not be obligated to do so, in seeking patent term restoration, extensions and/or any other extensions of the Zogenix Patents as permitted under Applicable Laws. Any costs associated with such patent term restoration or extensions of the Zogenix Patent shall be borne solely by Zogenix, subject to their rights under Section 9.2.",
    "contradiction_score": 0.02097848430275917,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 210,
    "start_char": 115916,
    "end_char": 117400,
    "original": "(a) Selection and Ownership of Product Trademarks.  All packaging, promotional materials, package inserts, and labeling for the Product in the Field in the Territory shall bear one or more Trademarks that pertain specifically to the Product, including the Trademarks in existence as of the Effective Date as set forth in Exhibit 9.8 (each, a \u201c Product Trademark \u201d). If the Product Trademarks in existence as of the Effective Date are not eligible for trademark protection or for use in connection with the Product in the Field in the Territory or if the Parties agree that alternative or additional Trademarks may be beneficial, Distributor may investigate appropriate Trademarks for the Product in the Territory. If the Parties identify and agree on alternative or additional Trademarks for the Product in the Territory, Zogenix shall use Commercially Reasonable Efforts to register such Trademark(s) for the Product in the Field in the Territory. Zogenix or its Affiliates shall own all right, title, and interest in and to all Product US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 Trademarks, all corresponding trademark applications and registrations thereof, and all common law rights thereto. All goodwill of the business associated with or symbolized by the Product Trademarks shall inure to the benefit of Zogenix. Distributor acknowledges Zogenix\u2019s exclusive ownership of the Product Trademarks and agrees not to take any action inconsistent with such ownership.",
    "ollama_generated": "(a) Designation and Ownership of Product Branding Assets. The product packaging, promotional materials, package inserts, and labeling within the Territory for the Field shall carry branding assets exclusive to the Product, including those identified in Exhibit 9.8 as of the Effective Date (each, a \"Product Branding Asset\"). If, at the Effective Date or thereafter, it is determined that the existing Product Branding Assets are unprotectable under trademark law or not suitable for use in connection with the Product within the Field and Territory, Distributor shall have the right to propose alternative or supplementary branding assets. Upon mutual agreement between the Parties on proposed alternatives or additions, Distributor shall make a reasonable effort to register such new branding assets for the Product within the Field and Territory. It is understood that Zogenix or its Affiliates retain all rights, title, and interest in the Product Branding Assets, corresponding trademark applications and registrations, and any common law rights arising from them. All goodwill generated by the business associated with or symbolized by the Product Branding Assets shall accrue to Zogenix's benefit. Distributor acknowledges and accepts Zogenix's exclusive ownership of the Product Branding Assets and agrees not to take any action that conflicts with such ownership.\n\nNote: This clause has been rewritten to shift some of the responsibility for investigating, registering, and proposing new branding assets (Trademarks) from Zogenix to the Distributor, provided that such assets are found to be unprotectable or not suitable for use in the agreed-upon Field and Territory. Additionally, it clarifies that any goodwill generated by the business associated with the branding assets will accrue to Zogenix's benefit.",
    "contradiction_score": 0.10771504789590836,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 211,
    "start_char": 117400,
    "end_char": 117802,
    "original": "(b) Maintenance and Prosecution of Product Trademarks.  Zogenix shall, at Zogenix\u2019s sole expense, control the registration, prosecution and maintenance of the Product Trademarks in the Territory\u037e provided, that Zogenix shall keep Distributor reasonably informed of Zogenix\u2019s actions with respect thereto and shall consider in good faith any reasonable comments made by Distributor with respect thereto.",
    "modified": "(b) Trademark Maintenance and Legal Actions: Distributor shall, at its sole expense, manage the registration, defense, and upkeep of the Product Trademarks within the Territory; however, Distributor will be expected to share essential information about these actions with Zogenix in a timely manner and take into account any reasonable suggestions made by Zogenix concerning such matters. The responsibility lies primarily with Distributor for this process, with Zogenix playing an advisory role.",
    "contradiction_score": 0.9675822257995605,
    "kept": true
  },
  {
    "clause_index": 214,
    "start_char": 120512,
    "end_char": 121326,
    "original": "US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 (e) Distributor\u2019s Housemarks.  In addition to the Product Trademarks, Distributor shall have the right to brand the Product in the Territory with those trademarks of Distributor that are associated with Distributor\u2019s name or identity and are pre-approved in writing by Zogenix (\u201c Distributor Housemarks \u201d). Distributor shall own all rights in the Distributor Housemarks, and all goodwill in the Distributor Housemarks shall accrue to Distributor. Distributor and its Affiliates and Sub-distributor shall not use any trademarks, other than the Zogenix Trademarks, Product Trademarks and the approved Distributor Housemarks, in connection with the Commercialization of the Product in the Field in the Territory, without the prior written consent of Zogenix.",
    "modified": "US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 (e) Distributor\u2019s Housemarks. Zogenix grants the Distributor the non-exclusive right to brand the Product in the Territory with those trademarks of Distributor that are associated with Distributor\u2019s name or identity and are pre-approved in writing by Zogenix (\u201cDistributor Housemarks\u201d). However, Zogenix retains ownership of all rights in the Distributor Housemarks, and any goodwill generated by the use of these marks will be deemed to belong exclusively to Zogenix. The Distributor, its Affiliates, and Sub-distributors may utilize only the Zogenix Trademarks, Product Trademarks, and the approved Distributor Housemarks in connection with the Commercialization of the Product in the Field within the Territory, with the prior written consent of Zogenix being optional but recommended.",
    "contradiction_score": 0.9416491389274597,
    "kept": true
  },
  {
    "clause_index": 225,
    "start_char": 125655,
    "end_char": 125965,
    "original": "(i) Notification for Violation of Applicable Laws . Such Party shall immediately notify the other Party if it has any information or suspicion that there may be a violation of the FCPA or any other Applicable Law in connection with the performance of this Agreement or the sale of the Product in the Territory.",
    "modified": "(ii) Non-Notification for Compliance with Applicable Laws . Neither Party shall have an obligation to notify the other Party if it does not have any information or suspicion that a violation of the FCPA or any other Applicable Law in connection with the performance of this Agreement or the sale of the Product in the Territory has occurred, provided that such non-notification shall not be construed as a waiver of any right to assert a claim for any actual violations discovered at a later time.",
    "contradiction_score": 0.9126091003417969,
    "kept": true
  },
  {
    "clause_index": 229,
    "start_char": 127267,
    "end_char": 128936,
    "original": "(i) Zogenix will have the right, upon reasonable prior written notice and during Distributor\u2019s regular business hours, to audit Distributor\u2019s and its Affiliates\u2019 books and records by an independent certified public accounting firm of recognized international standing, and Distributor shall ensure that Zogenix has the right to audit its Sub-distributors\u2019 and subcontractors\u2019 books and records, to investigation potential violations of any of the representations, warranties or covenants in this Section 10.2, the FCPA or other Applicable Laws or Distributor\u2019s compliance policies. Such audit may be made no more than once each Fiscal Year (unless an audit reveals a violation under this Agreement, in which case an additional audit may be conducted within such Fiscal Year)\u037e (ii) Distributor will certify to Zogenix annually in writing or otherwise upon Zogenix\u2019s written request, under the form set forth in Exhibit 10.2(b) attached hereto, Distributor\u2019s compliance with the representations, warranties and covenants in this Section 10.2, the FCPA and other Applicable Laws and Distributor\u2019s compliance policies\u037e (iii) Distributor will inform Zogenix promptly of any changes in its business that would change any of its representations, warranties or covenants in this Section 10.2\u037e (iv) Zogenix shall have the right to suspend or terminate the supply of Product under the Supply Agreement and to terminate this Agreement if there is credible evidence that Distributor or its Affiliate or Sub-distributor may have violated any of the representations, warranties or covenants in this Section 10.2 the FCPA or other Applicable Laws or Distributor\u2019s compliance policies.",
    "ollama_generated": "(i) Distributor grants Zogenix, upon a reasonable notice in writing during Distributor's regular business hours, the authority to audit, through an independent certified public accounting firm of international repute, Distributor's and its Affiliates' books and records, as well as those of its Sub-distributors and subcontractors. This audit is intended to investigate potential breaches of any representations, warranties, or covenants within Section 10.2, the FCPA, other Applicable Laws, or Distributor's compliance policies. Audits will be conducted no more than once per Fiscal Year unless an audit reveals a violation under this Agreement, in which case additional audits may be conducted within the same Fiscal Year. (ii) Zogenix is responsible for annually certifying, in writing or upon Distributor's request, that it has reviewed Distributor\u2019s compliance with the representations, warranties, and covenants in Section 10.2, the FCPA, other Applicable Laws, and Distributor\u2019s compliance policies, using a form outlined in Exhibit 10.2(b) attached herein. (iii) Zogenix will be notified by Distributor promptly of any modifications in its business that could impact the representations, warranties, or covenants within Section 10.2. (iv) Distributor understands and accepts that Zogenix retains the discretion to continue supplying Products under the Supply Agreement and maintaining this Agreement if there is no credible evidence of a violation by Distributor, its Affiliate, or Sub-distributor concerning any representations, warranties, or covenants in Section 10.2, the FCPA, other Applicable Laws, or Distributor\u2019s compliance policies. In the event of such evidence, Zogenix reserves the right to suspend or terminate the supply of Products under the Supply Agreement and terminate this Agreement.",
    "contradiction_score": 0.018773820251226425,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 237,
    "start_char": 132180,
    "end_char": 132859,
    "original": "(a) the manufacture, use, handling, storage, import, offer for sale, sale or other disposition of the Product outside the Territory by or on behalf of Zogenix or its Affiliates\u037e (b) the negligence or willful misconduct of any Zogenix Indemnitees in connection with Zogenix\u2019s performance of its obligations or exercise of its rights under this Agreement\u037e or (c) any breach of any representations, warranties or covenants of Zogenix in this Agreement, except to the extent such Third Party Claims fall within the scope of the indemnification obligations of Distributor set forth in Section 11.1 or arise out of the breach by Distributor of any of the terms of the Supply Agreement.",
    "modified": "(a) Any action taken, including manufacturing, using, handling, storing, importing, offering for sale, selling or otherwise disposing of the Product within the Territory by or on behalf of Distributor or its Affiliates; (b) any negligence or willful misconduct of any Distributor Indemnitees in relation to Distributor's obligations or exercise of rights under this Agreement; or (c) any breach of any representations, warranties, or covenants by Distributor as outlined in this Agreement, except for claims made against Zogenix that fall within the scope of the indemnification obligations of Zogenix as specified in Section 11.1, or claims arising from Distributor's breach of any terms in the Supply Agreement.",
    "contradiction_score": 0.7506604194641113,
    "kept": true
  },
  {
    "clause_index": 242,
    "start_char": 134834,
    "end_char": 134853,
    "original": "12.2  Termination .",
    "ollama_generated": "12.2 Termination Provisions:\n\nUpon the occurrence of any of the events outlined below, either Party shall have the right to terminate this Agreement, effective immediately and without prejudice, unless otherwise specified in writing by the terminating Party:\n\na) Material breach of any provision of this Agreement by the other Party that is not cured within thirty (30) days after receipt of written notice; or\n\nb) The insolvency or bankruptcy of either Party, or the filing of a petition in bankruptcy against either Party.\n\nHowever, termination by either Party shall not release such terminating Party from any liabilities accrued prior to the effective date of termination.",
    "contradiction_score": 0.03554875776171684,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 243,
    "start_char": 134854,
    "end_char": 134946,
    "original": "(a) Mutual Agreement.  The Parties may terminate this Agreement by mutual written agreement.",
    "modified": "(a) Unilateral Termination Option. One Party shall have the right to terminate this Agreement upon providing written notice to the other, if not responded within a reasonable timeframe, the non-terminating Party shall be deemed to have also consented to the termination.",
    "contradiction_score": 0.5220637321472168,
    "kept": true
  },
  {
    "clause_index": 247,
    "start_char": 136116,
    "end_char": 136620,
    "original": "Notwithstanding the foregoing, (a) if such material breach (other than a payment breach), by its nature, is curable, but is not reasonably curable within the [***]  period, then such period shall be extended if the breaching Party provides a written plan for curing such breach to the non-breaching Party and uses Commercially Reasonable Efforts to cure such breach in accordance with such written plan\u037e provided, that no such extension shall exceed [***]  without the consent of the non-breaching Party.",
    "ollama_generated": "Despite the preceding terms, if a material breach (other than a payment default), not inherently swift to remedy, persists beyond the initial specified duration and the breaching Party fails to present a viable written plan for rectification within that timeframe, then such a duration may be renegotiated. This renegotiation is contingent upon the breaching Party submitting a corrective action plan to the non-breaching Party and making Good Faith Efforts to rectify the breach in accordance with this proposed plan. Note that any extension beyond the initially specified period will require the approval of the non-breaching Party, and no such prolongation shall last more than [***] without such consent.",
    "contradiction_score": 0.02180514484643936,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 249,
    "start_char": 136728,
    "end_char": 137203,
    "original": "(f) Bankruptcy . A Party shall have the right to terminate this Agreement upon written notice to the other Party upon the bankruptcy, dissolution or winding up of such other Party, or the making or seeking to make or arrange an assignment for the benefit of creditors of such other Party, or the initiation of proceedings in voluntary or involuntary bankruptcy, or the appointment of a receiver or trustee of such other Party\u2019s property, that is not discharged within [***] .",
    "ollama_generated": "(f) Financial Distress . Either Party shall retain the discretion to suspend their obligations under this Agreement upon written notification to the other Party in case of financial distress, bankruptcy, dissolution, or winding up of the other Party; or any proceedings initiated by the other Party for a voluntary or involuntary reorganization, composition, arrangement, readjustment of debt, or similar relief under applicable laws; or if a receiver, trustee, liquidator, or similar agent is appointed to manage the property of the other Party. Such discretion to suspend shall remain in effect until the financial distress situation is resolved and the other Party has demonstrated stable financial health for a period of [***].",
    "contradiction_score": 0.006100350525230169,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 251,
    "start_char": 138303,
    "end_char": 138327,
    "original": "(h) Third Party Patent .",
    "ollama_generated": "(h) External Patent Licensing Commitment:\n\nThe Licensee hereby acknowledges its obligation to promptly provide the Licensor with a written notice whenever it becomes aware of any third-party claims, demands, actions or allegations that the products or services developed, used, marketed or sold under this Agreement may infringe upon patents held by others. The Licensor shall have the discretion but not the obligation to assist the Licensee in securing a license for such third-party patents on commercially reasonable terms, and the costs associated with such licensing efforts shall be borne solely by the Licensee.",
    "contradiction_score": 0.07079426199197769,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 252,
    "start_char": 138327,
    "end_char": 139207,
    "original": "(i) Distributor shall have the right to terminate this Agreement upon written notice to Zogenix if (A) the Parties have discussed an issued Patent under Section 9.4(a), (B) either (1) both Zogenix and Distributor agree not to seek a license under such issued Patent or (2) the applicable Party as determined pursuant to Section 9.4(a) failed to obtain a license under such issued Patent, after good faith efforts to do so, within [***]  after the Parties\u2019 agreement as to which Party would seek such license, and (C) Distributor reasonably and in good faith believes that the sale, offer for sale or import of the Product in the Territory in the Field infringes such issued Patent in the Territory, such that Distributor is not able to sell the Product in US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 the Territory in the Field without infringing such issued Patent.",
    "ollama_generated": "(i) This Agreement may be terminated by Distributor at any time upon providing written notice to Zogenix if:\n\n   (A) The Parties have held discussions concerning an issued Patent as outlined in Section 9.4(a);\n\n   (B) Neither Party has expressed interest in obtaining a license under such issued Patent, or;\n\n      - Both Zogenix and Distributor concur that no licensing will occur, or\n      - The determination made pursuant to Section 9.4(a) suggests that the Party responsible for seeking a license has failed to secure one after a reasonable period of good faith efforts, commencing from the moment both Parties have agreed on which Party would pursue such license;\n\n   (C) Distributor, acting in good faith and with a reasonable belief, deems that the sale, offering for sale, or importation of the Product within the Territory and Field may infringe upon the issued Patent within the Territory, to an extent that Distributor finds it impossible to market the Product in the specified Territory without potentially violating said Patent.\n\n   Notwithstanding the foregoing, this right to terminate remains solely at the discretion of the Distributor and is not contingent upon any findings or determinations by Zogenix regarding patent infringement.",
    "contradiction_score": 0.047107286751270294,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 253,
    "start_char": 139207,
    "end_char": 140088,
    "original": "(ii) Zogenix shall have the right to terminate this Agreement upon written notice to Distributor if (A) the Parties have discussed an issued Patent under Section 9.4(a), (B) either (1) both Zogenix and Distributor agree not to seek a license under such issued Patent or (2) the applicable Party as determined pursuant to Section 9.4(a) failed to obtain a license under such issued Patent, after good faith efforts to do so, within [***]  after the Parties\u2019 agreement as to which Party would seek such license, and (C) Zogenix reasonably and in good faith believes that the manufacture for and sale to Distributor of the Product infringes such issued Patent, such that Zogenix will not be able to conduct (or have conducted on its behalf) such manufacturing for and sale of the Product to Distributor without infringing (or its contract manufacturers infringing) such issued Patent.",
    "ollama_generated": "(ii) Distributor may receive a termination notice from Zogenix at their discretion, in writing, under the following conditions: (A) Following a discussion regarding an issued Patent as stipulated in Section 9.4(a), (B) if either Party chooses not to pursue a license under the mentioned Patent, or (C) if Zogenix, acting reasonably and in good faith, perceives that the manufacture of the Product for distribution to Distributor potentially infringes upon such issued Patent, thereby rendering it impossible for Zogenix or its contractors to continue manufacturing the Product for distribution to Distributor without infringing upon said Patent. It is worth noting that this termination right does not become effective until the timeframe specified in Section 9.4(a) has expired, and if neither Party succeeds in obtaining a license under the said Patent after making good faith efforts to do so during this period.",
    "contradiction_score": 0.003442462533712387,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 257,
    "start_char": 141855,
    "end_char": 142512,
    "original": "(l) Distributor Safety Concern . This Agreement may be terminated by Distributor upon written notice to Zogenix, in the event that Distributor has a reasonable belief after due inquiry that the promotion of the Product in the Field in the Territory presents a substantial risk of harm or injury to consumers which risk is unacceptable according to established principles of medical ethics. Prior to terminating this Agreement in accordance with this Section 12.2(l), Distributor shall present evidence supporting the basis for such termination to Zogenix and shall consider in good faith all comments provided by Zogenix prior to terminating this Agreement.",
    "modified": "(m) Zogenix Safety Concern: This Agreement can be terminated by Zogenix upon written notice to Distributor, if Zogenix has a reasonable belief after due inquiry that the promotion of the Product in the Field within the Territory poses a substantial risk of harm or injury to consumers, which risk Zogenix deems unacceptable according to established principles of medical ethics. Prior to terminating this Agreement under this Section 12.2(m), Zogenix shall present evidence supporting the basis for such termination to Distributor and shall consider in good faith all responses or defenses provided by Distributor before taking action.\n\nThis revision places the responsibility of termination on Zogenix, and requires them to provide evidence and consider any responses from Distributor before acting.",
    "contradiction_score": 0.7735645174980164,
    "kept": true
  },
  {
    "clause_index": 259,
    "start_char": 142664,
    "end_char": 143844,
    "original": "(a) Termination of Rights and Obligations . Upon termination of this Agreement, all rights and obligations of the Parties under this Agreement will terminate, except as provided in this Section 12.3 and Sections 12.4, 12.5 and 12.6. Within [***]  after the effective date of termination of this Agreement, each Party shall deliver to the other Party any and all Confidential Information of such other Party then in its possession, except to the extent a Party retains the right to use such Confidential Information pursuant to any rights granted under this Agreement that survive termination of this Agreement, and except for one (1) copy which may be kept in such Party\u2019s (or its counsel\u2019s) office for archival purposes subject to a continuing obligation of confidentiality and non-use under Article 8 for the duration set forth in Section 8.1. Neither Party shall be required to destroy Confidential Information contained in any electronic back-up tapes or other electronic back-up files that have been created solely by its automatic or routine archiving and back-up procedures, to the extent created and retained in a manner consistent with its standard archiving and back-up.",
    "modified": "(a) Survival of Rights and Obligations . Upon termination of this Agreement, only a select number of rights and obligations of the Parties under this Agreement will persist, as outlined in Sections 12.3, 12.4, 12.5, and 12.6. Within [***] following the effective date of termination, each Party shall provide to the other Party any and all Confidential Information belonging to the other Party that is currently in its possession. However, a Party may retain the right to utilize such Confidential Information according to the permissions granted under this Agreement that persist post-termination, provided it adheres to the continuing obligations of confidentiality and non-use as detailed in Article 8 for the duration specified in Section 8.1. No Party will be compelled to erase Confidential Information from any electronic back-up tapes or other electronic back-up files created through automatic or routine archiving and backup processes, only if such retention is consistent with standard archiving and backup procedures.",
    "contradiction_score": 0.7282768487930298,
    "kept": true
  },
  {
    "clause_index": 269,
    "start_char": 152322,
    "end_char": 152333,
    "original": "ARTICLE 13.",
    "ollama_generated": "ARTICLE 13 (MODIFIED DUTY OF CARE)\n\nIn the event that Party A provides any service or product to Party B under this Agreement, it is understood and agreed by both parties that Party A shall exercise reasonable care in performing its duties. However, Party A shall not be held liable for any indirect, special, incidental, or consequential damages resulting from such services or products, unless such damages were directly caused by Party A's gross negligence or intentional misconduct. This limitation of liability applies regardless of whether Party B has been advised of the possibility of such damages.",
    "contradiction_score": 0.009038730524480343,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 279,
    "start_char": 155963,
    "end_char": 157042,
    "original": "14.2  Force Majeure . Neither Party shall be held liable to the other Party nor be US-DOCS\\105216871.19 Source: ZOGENIX, INC., 10-Q, 5/9/2019 deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement (other than failure to make payment when due) when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including embargoes, war, acts of war (whether war be declared or not), insurrections, riots, fire, floods, or other acts of God, or acts, omissions or delays in acting by any governmental authority or the other Party. The affected Party shall notify the other Party of such force majeure circumstances as soon as reasonably practicable, and shall promptly undertake all reasonable efforts necessary to cure such force majeure circumstances. Such excuse from liability shall be effective only to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur.",
    "ollama_generated": "14.2 Force Majeure Exemption: Neither Party will be considered in breach of this Agreement nor liable to the other for any delay or failure to perform its obligations (other than payment obligations), if such delay or failure results from unforeseeable events beyond its reasonable control, including but not limited to embargoes, war, acts of war (whether declared or not), insurrections, riots, fire, floods, natural disasters, or other acts of nature. In such circumstances, the affected Party must notify the other Party as soon as possible and take all reasonable steps to resolve the situation. This exemption from liability applies only for the duration of the event(s) causing the performance issue, and provided that the Party did not intentionally cause the event(s).",
    "contradiction_score": 0.016566921025514603,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 288,
    "start_char": 159997,
    "end_char": 160100,
    "original": "Latham & Watkins, LLP 12670 High Bluff Drive San Diego, CA 92130, U.S.A Attention: Cheston Larson, Esq.",
    "ollama_generated": "Addressee: Cheston Larson, Esq., Latham & Watkins, LLP, 12670 High Bluff Drive, San Diego, CA 92130, U.S.A\n\nSubject: Modification of Clause Regarding Responsibility Sharing\n\nDear Mr. Larson,\n\nIn our previous correspondence regarding the matter at hand, it was stipulated that [Company Name] is responsible for certain actions. We are writing to amend this clause in order to clarify that while [Company Name] shall continue to act diligently and professionally in fulfilling its obligations, Latham & Watkins, LLP assumes joint responsibility for the outcome of any actions taken under this agreement.\n\nWe trust that this modification will be acceptable to your esteemed firm, as we view it as an opportunity to strengthen our working relationship and collaborate more effectively on behalf of our mutual clients.\n\nShould you have any questions or concerns regarding this amendment, please do not hesitate to contact us at [Company Contact Information]. We look forward to continuing our productive partnership.\n\nBest regards,\n\n[Your Name]\n[Your Title]\n[Your Company Name]",
    "contradiction_score": 0.002039483981207013,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 289,
    "start_char": 160100,
    "end_char": 160168,
    "original": "Facsimile Number: +1 (858) 523-5450 If to Distributor, addressed to:",
    "ollama_generated": "Alternative Contact Method: Electronic Mail [distributor@emaildomain.com], should physical delivery be inconvenient or impossible. Communication to Vendor shall be deemed received upon confirmation of receipt.\n\nThis revised clause offers an alternative method of communication, electronic mail, in case physical delivery is inconvenient or impossible. This change may reflect a more flexible and modern approach to communication. However, it's essential to note that the vendor still requires a confirmation of receipt for any communication sent via email, ensuring that the vendor can prove the transmission has taken place, which is crucial in legal matters.",
    "contradiction_score": 0.0012109859380871058,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 292,
    "start_char": 160714,
    "end_char": 161435,
    "original": "14.6  Entire Agreement\u037e Amendments . This Agreement and the Supply Agreement, together with the exhibits hereto and thereto, contain the entire understanding of the Parties with respect to the subject matter hereof and thereof and supersede and cancel all previous express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, in respect to the subject matter hereof and thereof, including the Confidentiality Agreement. This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both Parties, but \u201cwritten instrument\u201d does not include the text of e-mails or similar electronic transmissions.",
    "ollama_generated": "14.6 Scope and Modifications: This Agreement, along with the Supply Agreement, their accompanying exhibits, represent a summary of our mutual understanding regarding the specified subject matter. Any prior oral or written agreements, negotiations, communications, or representations, whether express or implied, that pertain to this matter are now considered null and void.\n\nAny amendments to this Agreement or modifications to its terms shall require a signed document executed by duly authorized representatives from both Parties. However, the term \"signed document\" does not encompass electronic communications such as emails. Nonetheless, any deviations from the terms of this Agreement arising from oral discussions or implied understandings will not be binding unless explicitly agreed upon and documented in writing by both Parties.",
    "contradiction_score": 0.009457810781896114,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 302,
    "start_char": 165052,
    "end_char": 165321,
    "original": "14.16  Further Actions . Each Party will execute, acknowledge and deliver such further instruments, and to do all such other ministerial, administrative or similar acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement.",
    "ollama_generated": "14.16 Additional Requirements: Each Party shall be prepared to sign, acknowledge, and deliver any additional documents, and perform any minor, administrative, or similar tasks that might be required for the effective execution of this Agreement's objectives. However, it is understood that such requests will only be made when absolutely necessary and with reasonable justification provided.",
    "contradiction_score": 0.003253739792853594,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 306,
    "start_char": 166325,
    "end_char": 166594,
    "original": "Appointment as Exclusive Supplier . During the Term, Zogenix shall retain and have the sole and exclusive right to supply or have supplied all of Distributors\u2019 and its Affiliates\u2019 and Sub-distributors\u2019 requirements of the Product for sale in the Field in the Territory.",
    "ollama_generated": "Exclusivity in Supply Arrangement . For the duration of the Term, Distributors shall be obliged to primarily procure, unless otherwise agreed in writing, all their own requirements and those of their Affiliates and Sub-distributors, related to the Product, from Zogenix for resale within the defined Field and Territory. Any deviations must receive prior written consent from Zogenix.",
    "contradiction_score": 0.006450005806982517,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 307,
    "start_char": 166594,
    "end_char": 167643,
    "original": "Transfer Price.  The price at which Zogenix supplies the Product (as Unlabeled Drug Product) to Distributor equals the consideration and Transfer Price set forth in the Agreement in Section 6.5. Distributor shall make payment in accordance with Sections 6.1, 6.3, and 6.4, and shall also pay Zogenix\u2019s invoice for the estimated Transfer Price within [***]  of the date on which the applicable units of Product are delivered by Zogenix in accordance Section 6.5 and the terms of the Supply Agreement. The Parties will true-up the Fully-Burdened Manufacturing Cost on an annual basis when truing-up the Transfer Price. For any Product that is supplied to Distributor under this Agreement and damaged by Distributor during labeling or packaging, the transfer price for any such Product shall be [***]  per unit of Product for the applicable Fiscal Year. The Supply Agreement shall also include terms permitting Distributor to audit Zogenix\u2019s Fully-Burdened Manufacturing Costs that are similar to Zogenix\u2019s audit rights in Section 7.5 of the Agreement.",
    "modified": "Transfer Price Adjustment: The price at which Distributor purchases the Product (as Unlabeled Drug Product) from Zogenix will be determined by the consideration and Transfer Price outlined in the Agreement under Section 6.5. Zogenix will submit an invoice for the estimated Transfer Price, payable by Distributor within [***] of the delivery date specified in Section 6.5 and the Supply Agreement terms. The Parties will perform an annual reconciliation of Fully-Burdened Manufacturing Costs to adjust the Transfer Price accordingly. In the event that any Product supplied under this Agreement is damaged by Distributor during labeling or packaging, Zogenix will absorb the associated costs and the transfer price for such affected units shall not be adjusted. The Supply Agreement will also incorporate provisions enabling Zogenix to audit Distributor's Fully-Burdened Manufacturing Costs, mirroring Distributor's audit rights as detailed in Section 7.5 of the Agreement.",
    "contradiction_score": 0.6931214928627014,
    "kept": true
  },
  {
    "clause_index": 317,
    "start_char": 171416,
    "end_char": 172019,
    "original": "Regulatory Audits . Not more than once per Fiscal Year or as otherwise agreed by the Parties, and subject to the terms of the applicable agreement between Zogenix and its Third Party manufacturers, Zogenix shall, at Distributor\u2019s request, conduct GMP audits of the Third Party manufacturers and, if applicable, exercise such other audit rights that Zogenix may have under such agreements, and shall disclose to Distributor the results of such audits. Zogenix will use commercially reasonable efforts to cause such Third Party manufacturers to promptly correct any deficiencies or other adverse findings.",
    "ollama_generated": "Regulatory Audits: At least once a Fiscal Year, or as mutually agreed by the Parties, Distributor may request Zogenix to perform GMP audits on Third Party manufacturers. If applicable, Zogenix will exercise any audit rights granted under the pertinent agreements with its Third Party manufacturers. The results of these audits will be shared with the Distributor. While Zogenix will strive to promptly address any identified deficiencies or adverse findings, it is the responsibility of the Third Party manufacturers to correct these issues in a timely manner. Zogenix's efforts are subject to the terms and conditions outlined within the respective agreements between itself and its Third Party manufacturers.",
    "contradiction_score": 0.0011871954193338752,
    "kept": false,
    "reason": "low_contradiction"
  }
]